If you’ve had genetic testing for increased risk of breast and ovarian cancer you might be surprised. One company owns the patent on two of those genes known as BRCA1 and BRCA2. The ACLU and The Public Patent Foundation have filed a lawsuit challenging the government’s practice of granting patents on human genes.
The tests for BRCA1 and BRCA2 are expensive, not always covered by insurance, and no one can get a second opinion, the ACLU said. Some patients who are tested are unaware that one company has sole control over the research and testing of these genes.